monoclonal antibody Archives - PharmaDeviceNews

Representative image: Biologic vial and infusion setup for multiple sclerosis care, highlighting Teva Pharmaceutical Industries’ Polpharma Biologics deal for a proposed ocrelizumab biosimilar.

Teva and Polpharma Biologics sign global ocrelizumab biosimilar licensing deal

by Venkatesh B
July 11, 2026
0 Comments

Teva Pharmaceutical Industries Ltd. has secured exclusive global commercialization rights to Polpharma Biologics’ proposed biosimilar to Ocrevus ocrelizumab for multiple sclerosis, covering both intravenous and subcutaneous formulations upon regulatory approval. Polpharma Biologics will remain responsible for development and manufacturing, while Teva will handle regulatory submissions and commercialization across major markets including the United States, Europe,

Representative image: A neurology consultation scene highlights the growing clinical focus on migraine prevention as Lundbeck’s bocunebart Phase IIb data strengthen interest in PACAP-targeted therapies for patients with hard-to-treat migraine.

Pharma & Biotech

Why Lundbeck’s anti-PACAP migraine drug could matter beyond another Phase II win

by Pallavi Madhiraju
June 5, 2026
0 Comments

Find out how Lundbeck’s bocunebart Phase IIb data could reshape migraine prevention and test the PACAP pathway.

Pharma & Biotech

Marea Therapeutics targets acromegaly treatment burden with long-acting MAR002 antibody

by Pallavi Madhiraju
May 27, 2026
0 Comments

Daily acromegaly injections face a convenience challenge. Marea’s MAR002 could reset expectations if Phase 1 durability translates.

Pharma & Biotech

Why the market will watch Calluna Pharma’s CAL101 more closely after AURORA enrollment ends ahead of plan

by Pallavi Madhiraju
April 22, 2026
0 Comments

Calluna Pharma finished Phase 2 AURORA enrollment early for CAL101 in IPF. Read what this means for fibrosis competition and Q1 2027 data.

Pharma & Biotech

How Merck’s ENFLONSIA could challenge existing infant RSV prevention pathways in Europe

by Pallavi Madhiraju
April 19, 2026
0 Comments

European Union approval gives Merck’s ENFLONSIA a new opening in infant RSV prevention. Read what it means for rollout, reimbursement, and competition.

Pilatus Biosciences moves beyond PD 1 with FDA backed Fast Track pathway for PLT012

Pharma & Biotech

Can targeting CD36 reshape hepatocellular carcinoma immunotherapy? Pilatus Biosciences takes first step

by Pallavi Madhiraju
February 20, 2026
0 Comments

Pilatus Biosciences earns FDA Fast Track for PLT012 in liver cancer. Read why CD36 targeting could reshape immunotherapy development.

Pharma & Biotech

How amlitelimab’s dosing flexibility could disrupt biologic treatment patterns in atopic dermatitis

by Soujanya Ravi
January 23, 2026
0 Comments

Sanofi’s amlitelimab advances toward filing in atopic dermatitis. Explore how dosing flexibility, durability data, and regional results shape its outlook.

Representative image: GSK to acquire RAPT Therapeutics for $2.2 billion, strengthening its immunology pipeline with ozureprubart, a long-acting anti-IgE therapy in development for food allergy protection. The asset could shift standard care by enabling quarterly dosing.

Pharma & Biotech

Can GSK’s $2.2bn acquisition of RAPT Therapeutics reshape the food allergy treatment landscape with ozureprubart?

by Pallavi Madhiraju
January 20, 2026
0 Comments

GSK plc has signed a definitive agreement to acquire RAPT Therapeutics Inc., a clinical-stage biopharmaceutical company based in California, in a transaction valued at approximately $2.2 billion. The centerpiece of the deal is ozureprubart, a long-acting anti-IgE monoclonal antibody currently undergoing Phase IIb evaluation for the prophylactic treatment of food allergies. With topline data from